0001140361-24-041788.txt : 20240924 0001140361-24-041788.hdr.sgml : 20240924 20240924210102 ACCESSION NUMBER: 0001140361-24-041788 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240920 FILED AS OF DATE: 20240924 DATE AS OF CHANGE: 20240924 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gline Matthew CENTRAL INDEX KEY: 0001750094 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 241321132 MAIL ADDRESS: STREET 1: C/O UROVANT SCIENCES, INC. STREET 2: 5151 CALIFORNIA AVENUE, SUITE 250 CITY: IRVINE STATE: CA ZIP: 92617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4.xml FORM 4 X0508 4 2024-09-20 0001635088 Roivant Sciences Ltd. ROIV 0001750094 Gline Matthew C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true true CEO true Common Shares 2024-09-20 4 F 0 10945 11.97 D 18303800 D Common Shares 2024-09-23 4 M 0 1550000 3.85 A 19853800 D Common Shares 2024-09-23 4 S 0 1983257 11.79 D 17870543 D Common Shares 2024-09-23 4 J 0 498539 11.97 D 17372004 D Stock Option (Right to Buy) 3.85 2024-09-23 4 M 0 1550000 0 D 2032-04-19 Common Stock 1550000 14973184 D Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. The reporting person does not expect to sell additional shares of the Issuer in the near future. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Represents the "net settlement" by the Issuer of options previously granted to the reporting person in order to satisfy the exercise price applicable to such options. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline 2024-09-24